209 related articles for article (PubMed ID: 20686877)
1. Successful treatment of cryoglobulinemic glomerulonephritis derived from Waldenström's macroglobulinemia by rituximab-CHOP and tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation.
Kawano N; Ikeda N; Yoshida S; Sugio Y; Yamashita K; Uezono S; Hayashi T; Hara S; Makino S; Shimoda K; Ueda A
Int J Hematol; 2010 Sep; 92(2):391-7. PubMed ID: 20686877
[TBL] [Abstract][Full Text] [Related]
2. [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Adam Z; Pour L; Krejčí M; Ševčíková S; Pourová E; Ševčíková E; Král Z; Mayer J
Vnitr Lek; 2016 Jan; 62(1):25-39. PubMed ID: 26967234
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of diffuse large B-cell lymphoma following Waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab.
Uchino K; Sameshima H; Miyamoto T; Iino T; Kato K; Henzan H; Aoki K; Nagafuji K; Gondo H; Harada M
Intern Med; 2004 Feb; 43(2):131-4. PubMed ID: 15005256
[TBL] [Abstract][Full Text] [Related]
4. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia.
Treon SP; Hunter Z; Barnagan AR
Clin Lymphoma; 2005 Mar; 5(4):273-7. PubMed ID: 15794864
[TBL] [Abstract][Full Text] [Related]
5. Waldenstrom macroglobulinemia with CD5+ expression presented as cryoglobulinemic glomerulonephropathy: a case report.
Kim YL; Gong SJ; Hwang YH; Joo JE; Cho YU; Lee JA; Sung SA; Lee SY; Kim NY
J Korean Med Sci; 2011 Jun; 26(6):824-8. PubMed ID: 21655071
[TBL] [Abstract][Full Text] [Related]
6. [Complete response achieved after rituximab plus CHOP therapy in a patient with rapidly progressing Waldenstrom's macroglobulinemia].
Ise M; Sakai C; Kumagai K
Rinsho Ketsueki; 2009 Jan; 50(1):34-8. PubMed ID: 19225227
[TBL] [Abstract][Full Text] [Related]
7. Alkylating Agents in the Treatment of Waldenström Macroglobulinemia.
Buske C
Hematol Oncol Clin North Am; 2018 Oct; 32(5):821-827. PubMed ID: 30190020
[TBL] [Abstract][Full Text] [Related]
8. [Osteonecrosis developing after rituximab-containing chemotherapy for Waldenström macroglobulinemia].
Nakamura F; Hirai R; Higo T; Togano T; Sekine R
Rinsho Ketsueki; 2018; 59(3):305-309. PubMed ID: 29618689
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
10. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
Buske C; Hoster E; Dreyling M; Eimermacher H; Wandt H; Metzner B; Fuchs R; Bittenbring J; Woermann B; Hohloch K; Hess G; Ludwig WD; Schimke J; Schmitz S; Kneba M; Reiser M; Graeven U; Klapper W; Unterhalt M; Hiddemann W;
Leukemia; 2009 Jan; 23(1):153-61. PubMed ID: 18818699
[TBL] [Abstract][Full Text] [Related]
11. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.
Treon SP; Gertz MA; Dimopoulos M; Anagnostopoulos A; Blade J; Branagan AR; Garcia-Sanz R; Johnson S; Kimby E; Leblond V; Fermand JP; Maloney DG; Merlini G; Morel P; Morra E; Nichols G; Ocio EM; Owen R; Stone MJ
Blood; 2006 May; 107(9):3442-6. PubMed ID: 16410453
[TBL] [Abstract][Full Text] [Related]
12. [MALT lymphoma accompanied by elevated serum IgM levels mimicking Waldenström's macroglobulinemia].
Izumi S; Kimura K; Takeda Y; Tsukamoto S; Yamazaki M; Mishina T; Nagai Y; Takaishi K; Nagao Y; Oshima-Hasegawa N; Mitsukawa S; Mimura N; Takeuchi M; Ohwada C; Iseki T; Ota S; Nakaseko C; Sakaida E
Rinsho Ketsueki; 2018; 59(12):2600-2605. PubMed ID: 30626796
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of post-remission therapy using (90)yttrium ibritumomab tiuxetan (Zevalin®) for high-risk patients with diffuse large B-cell lymphoma.
Han EJ; Lee SE; Kim SH; Sohn HS; Jung SE; Park G; Choi BO; Lee SN; Yang SW; Han K; Cho SG
Ann Hematol; 2011 Sep; 90(9):1075-82. PubMed ID: 21336624
[TBL] [Abstract][Full Text] [Related]
14. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.
Ioakimidis L; Patterson CJ; Hunter ZR; Soumerai JD; Manning RJ; Turnbull B; Sheehy P; Treon SP
Clin Lymphoma Myeloma; 2009 Mar; 9(1):62-6. PubMed ID: 19362976
[TBL] [Abstract][Full Text] [Related]
15. Recovery of kidney function by rituximab-based therapy in a patient with Waldenström's macroglobulinemia-related nephropathy presenting cast nephropathy and interstitial lymphocytic infiltration.
Miwa M; Sakao Y; Ishigaki S; Ono M; Fujikura T; Yasuda H; Suzuki H; Kato A; Nagata Y; Shigeno K; Nakamura S; Ohnishi K; Fujigaki Y
Intern Med; 2012; 51(13):1725-30. PubMed ID: 22790134
[TBL] [Abstract][Full Text] [Related]
16. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
[TBL] [Abstract][Full Text] [Related]
17. [Therapy of Waldenström´s macroglobulinaemia in the year 2014].
Adam Z; Krejčí M; Pour L; Ševčíková E
Vnitr Lek; 2014 Feb; 60(2):139-57. PubMed ID: 24754419
[TBL] [Abstract][Full Text] [Related]
18. Waldenström's Macroglobulinemia and Cryoglobulinemic Glomerulonephritis: An Unusual Case of Monoclonal Gammopathy of Renal Significance.
De La Flor JC; Sulca JM; Rodríguez P; Villa D; Sandoval E; Zamora R; Monroy-Condori M; Lipa R; Perez H; Cieza M
Med Sci (Basel); 2023 Dec; 11(4):. PubMed ID: 38132918
[TBL] [Abstract][Full Text] [Related]
19. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
Dimopoulos MA; Gertz MA; Kastritis E; Garcia-Sanz R; Kimby EK; Leblond V; Fermand JP; Merlini G; Morel P; Morra E; Ocio EM; Owen R; Ghobrial IM; Seymour J; Kyle RA; Treon SP
J Clin Oncol; 2009 Jan; 27(1):120-6. PubMed ID: 19047284
[TBL] [Abstract][Full Text] [Related]
20. [Bing-Neel syndrome revealing Waldenström's macroglobulinemia].
Drouet T; Behin A; Psimaras D; Choquet S; Guillevin R; Hoang Xuan K
Rev Neurol (Paris); 2010 Jan; 166(1):66-75. PubMed ID: 19403149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
